[go: up one dir, main page]

PL1652535T3 - Półstałe formulacje mukoadhezyjne - Google Patents

Półstałe formulacje mukoadhezyjne

Info

Publication number
PL1652535T3
PL1652535T3 PL04742064T PL04742064T PL1652535T3 PL 1652535 T3 PL1652535 T3 PL 1652535T3 PL 04742064 T PL04742064 T PL 04742064T PL 04742064 T PL04742064 T PL 04742064T PL 1652535 T3 PL1652535 T3 PL 1652535T3
Authority
PL
Poland
Prior art keywords
semi
mucoadhesive formulations
solid
solid mucoadhesive
formulations
Prior art date
Application number
PL04742064T
Other languages
English (en)
Inventor
Fernández Álvaro Acebrón
García Ana Campuzano
Martin Rosa Maria Hernández
Olaechea Manuela Igartua
Munoz José Luis Pedraz
Gascón Alicia Rodríguez
Original Assignee
Itf Res Pharma Slu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itf Res Pharma Slu filed Critical Itf Res Pharma Slu
Publication of PL1652535T3 publication Critical patent/PL1652535T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Adhesive Tapes (AREA)
PL04742064T 2003-07-16 2004-07-16 Półstałe formulacje mukoadhezyjne PL1652535T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301672A ES2237298B1 (es) 2003-07-16 2003-07-16 Formulaciones mucoadhesivas semisolidas.
PCT/ES2004/000336 WO2005007194A1 (es) 2003-07-16 2004-07-16 Formulaciones mucoadhesivas semisólidas
EP04742064A EP1652535B1 (en) 2003-07-16 2004-07-16 Semi-solid mucoadhesive formulations

Publications (1)

Publication Number Publication Date
PL1652535T3 true PL1652535T3 (pl) 2011-03-31

Family

ID=34072910

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04742064T PL1652535T3 (pl) 2003-07-16 2004-07-16 Półstałe formulacje mukoadhezyjne

Country Status (13)

Country Link
US (1) US8663688B2 (pl)
EP (2) EP1652535B1 (pl)
JP (1) JP4891765B2 (pl)
AT (1) ATE482723T1 (pl)
CY (1) CY1110954T1 (pl)
DE (1) DE602004029369D1 (pl)
DK (1) DK1652535T3 (pl)
ES (2) ES2237298B1 (pl)
HR (1) HRP20100635T1 (pl)
PL (1) PL1652535T3 (pl)
PT (1) PT1652535E (pl)
SI (1) SI1652535T1 (pl)
WO (1) WO2005007194A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
JP2007505927A (ja) 2003-09-19 2007-03-15 ドラッグテック コーポレイション 薬物送達システム
WO2006138715A1 (en) * 2005-06-16 2006-12-28 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
US10016442B2 (en) 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
EP1912623A2 (en) * 2005-08-12 2008-04-23 Drugtech Corporation Estrogen compositions and therapeutic methods of use thereof
US20070264309A1 (en) * 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
RS56044B1 (sr) * 2006-05-12 2017-09-29 Christian Noe Primena kombinovanih preparata koji sadrže antimikotike
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US20080003262A1 (en) * 2006-06-30 2008-01-03 Drugtech Corporation Compositions and therapeutic methods of use
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
ES2344673B1 (es) * 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
CN102176818A (zh) * 2008-08-12 2011-09-07 诺华贝制药公司 抗微生物凝胶制剂
BRPI0803568B8 (pt) * 2008-08-14 2021-05-25 Biolab San Us Farm Ltda composição mucoaderente
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
WO2011121074A1 (en) * 2010-04-01 2011-10-06 Pharmanest Ab Thermogelling anaesthetic compositions
CN102293735B (zh) * 2011-08-19 2013-05-01 辽宁万嘉医药科技有限公司 一种抗真菌咪唑类药物缓释凝胶和制备方法
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102600288B (zh) * 2012-04-20 2014-03-05 广西源安堂药业有限公司 一种治疗阴道炎的复方黄松凝胶药物及其制备方法
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
KR101358993B1 (ko) 2012-09-05 2014-02-06 임혜선 네일 프린팅용 트랜스퍼 솔루션 및 이를 이용한 네일 프린팅 방법
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US20160175271A1 (en) * 2014-12-19 2016-06-23 Gavis Pharmaceuticals Rectal suppository for ulcerative colitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017206048B2 (en) * 2016-01-07 2023-04-13 Viramal Limited Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
CN110151680A (zh) * 2019-04-10 2019-08-23 重庆医药高等专科学校 雌三醇凝胶产品及制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
NZ222698A (en) 1987-01-08 1990-02-26 Squibb & Sons Inc Bioadhesive suppository formulations comprising a medicament, water, a hydrocolloid and low melting point base
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DK0431719T3 (da) 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
DE69033199T2 (de) 1989-10-31 1999-10-28 Columbia Lab Bermuda Ltd Mittel zur feuchthaltung von gewebe und verfahren
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
ATE442844T1 (de) 1996-11-14 2009-10-15 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
DE69942774D1 (de) 1999-02-26 2010-10-28 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
SE522260C2 (sv) 1999-10-01 2004-01-27 Ericsson Telefon Ab L M Metod, system och säkerhetsadapter för att exekvera säker dataöverföring i ett trådlöst nät
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
AU778498B2 (en) * 1999-10-22 2004-12-09 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.

Also Published As

Publication number Publication date
HRP20100635T1 (hr) 2010-12-31
US20060240111A1 (en) 2006-10-26
EP1652535A1 (en) 2006-05-03
CY1110954T1 (el) 2015-06-11
ES2237298A1 (es) 2005-07-16
DK1652535T3 (da) 2010-11-15
EP2100612A2 (en) 2009-09-16
EP2100612A3 (en) 2010-06-02
DE602004029369D1 (de) 2010-11-11
EP1652535B1 (en) 2010-09-29
JP4891765B2 (ja) 2012-03-07
PT1652535E (pt) 2010-11-18
JP2007528864A (ja) 2007-10-18
SI1652535T1 (sl) 2010-12-31
ES2237298B1 (es) 2006-11-01
WO2005007194A1 (es) 2005-01-27
ES2353694T3 (es) 2011-03-04
US8663688B2 (en) 2014-03-04
ATE482723T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
PL1652535T3 (pl) Półstałe formulacje mukoadhezyjne
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
EP2000136A3 (en) Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2002241520A1 (en) Blood assessment of injury
TR200800691T2 (tr) Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
IL172423A0 (en) Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
WO2002051404A8 (fr) Compositions orales
HK1045942A1 (zh) 结合(s)-2-(苄胺甲基)-2，3，8，9，-四氢-7h-1，4-二氧(2，3)吲-8-酮及精神抑制药
IT1318509B1 (it) Polimeri reticolati, utili per uso farmaceutico, medicale e cosmetico.
RU2000104127A (ru) Штамм bacillus subtilis x-15, используемый для профилактики и лечения эндометритов у коров
WO2004006900A3 (en) Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases
WO2006062980A3 (en) Stable non-crystalline formulation comprising tiagabine
WO2005023288A8 (en) Treatment of fibrotic disease
ITBO20000360A0 (it) Apparecchiatura di elettrostimolazione del corpo umano .
UA36410A (uk) Спосіб аудіометричного обстеження слухової системи людини
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
WO2002083110A3 (en) Animal model for evaluating analgesics